Sex-related differences in heart failure

Management of Acute Decompensated Heart Failure

Volumn , Issue , 2005, Pages 53-70

  Ghali, Jalal K ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 71049168750     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9780203421345-9     Document Type: Chapter

References (133)

1. Institute of Medicine. Exploring the Biological Contributions to Human Health: Does Sex Matter? (National Academy Press: Washington DC, 2001).
2. Ghali JK. A clinician’s perspective on clinical trials. J Card Fail 2001; 7: 1-3.
3. Lindenfeld J, Krause-Steinrauf H, Salerno J. Where are all the women with heart failure? J Am Coll Cardiol 1997; 30: 1417-1419.
4. Petrie MC, Dawson NF, Murdoch DR, Davie AP, McMurray JJ. Failure of women’s hearts. Circulation 1999; 99: 2334-2341.
5. Hoppe BL, Hermann DD. Sex differences in the causes and natural history of heart failure. Curr Cardiol Rep 2003; 5: 193-199.
6. Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch Intern Med 2002; 162: 1682-1688.
7. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-1552.
8. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
9. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
10. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
12. The PROMISE Study Research Group. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-1475.
13. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333: 77-82.
14. Packer M, O’Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996; 335: 1107-1114.
15. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54.
16. Hampton JR, van Veldhuisen DJ, Kleber FX, et al. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomized Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators. Lancet 1997; 349: 971-977.
17. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
18. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-752.
19. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998; 339: 1810-1816.
20. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet 1999; 353: 9-13.
21. Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
22. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312-2318.
23. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
24. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-1587.
25. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
26. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675.
27. Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:2194-2199.
28. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
29. McMurray J, Ostergren J, Pfeffer M, et al. CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261-270.
30. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150.
31. American Heart Association. Heart Disease and Stroke Statistics-2003 Update (American Heart Association: Dallas, TX, 2003).
32. Ansari M, Massie BM. Heart failure: How big is the problem? Who are the patients? What does the future hold? Am Heart J 2003; 146: 1-4.
33. DHSS. Vital and Health Statistics: Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-94 (Hyattsville, MD: National Center for Health Statistics, Centers for Disease Control and Prevention, US Dept of Health and Human Services; 1994), 407.
34. Schocken DD, Arrieta ML, Leaverton PE, Ross, EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301-306.
35. Ni, H. Prevalence of self-reported heart failure among US adults: results from the 1999 National Health Interview Survey. Am Heart J 2003; 146:121-128.
36. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-1402.
37. Senni M, Tribouilloy CM, Rodeheffer RJ, et al. Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med 1999; 159: 29-34.
38. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-1562.
39. Ho KKL, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: The Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
40. Lloyd-Jones DM, Larson MG, Leip EP, et al. Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068-3072.
41. Koelling TM, Chen RS, Lubwama RN, L’Italien GJ, Eagle KA. The expanding national burden of heart failure in the United States: the influence of heart failure in women. Am Heart J 2004; 147: 74-78.
42. Redfield MM, Jacobsen SJ, Burnett JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
43. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995; 26: 1565-1574.
44. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction:prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999; 33: 1948-1955.
45. Senni M, Tribouilloy CM, Rodeheffer, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98: 2282-2289.
46. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. CHS Research Group, Cardiovascular Health Study. Am J Cardiol 2001; 87: 413-419.
47. Devereux RB, Roman MJ, Liu JE, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol 2000; 86: 1090-1096.
48. Masoudi FA, Havranek EP, Smith G, et al. Gender, age, and heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2003; 41:217-223.
49. Mendes LA, Davidoff R, Cupples LA, Ryan TJ, Jacobs AK. Congestive heart failure in patients with coronary artery disease: the gender paradox. Am Heart J 1997; 134: 207-212.
50. Carroll JD, Carroll EP, Feldman T, et al. Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation 1992; 86: 1099-1107.
51. Gerdts E, Zabalgoitia M, Björnstad H, Svendsen TL, Devereux RB. Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study). Am J Cardiol 2001; 87: 980-983.
52. Pfeffer JM, Pfeffer MA, Fletcher P, Braunwald E. Alterations of cardiac performance in rats with established spontaneous hypertension. Am J Cardiol 1979; 44: 994-998.
53. Litwin SE, Katz SE, Litwin CM, Morgan JP, Douglas PS. Gender differences in postinfarction left ventricular remodeling. Cardiology 1999; 91: 173-183.
54. Douglas PS, Katz SE, Weinberg EO, et al. Hypertrophic remodeling: gender differences in the early response to left ventricular pressure overload. J Am Coll Cardiol 1998; 32: 1118-1125.
55. Gardner JD, Brower GL, Janicki JS. Gender differences in cardiac remodeling secondary to chronic volume overload. J Card Fail 2002; 8: 101-107.
56. Tamura T, Said S, Gerdes AM. Gender-related differences in myocyte remodeling in progression to heart failure. Hypertension 1999; 33: 676-680.
57. Crabbe DL, Dipla K, Ambati S, et al. Gender differences in post-infarction hypertrophy in end-stage failing hearts. J Am Coll Cardiol 2003; 41: 300-306.
58. De Maria R, Gavazzi A, Recalcati F. et al. Comparison of clinical findings in idiopathic dilated cardiomyopathy in women versus men. The Italian Multicenter Cardiomyopathy Study Group (SPIC). Am J Cardiol 1993; 72: 580-585.
59. Adams KF Jr, Dunlap SH, Sueta CA, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol 1996; 28: 1781-1788.
60. Adams KF Jr., Sueta CA, Gheorghiade M, et al. Gender differences in survival in advanced heart failure. Insights from the FIRST study. Circulation 1999; 99: 1816-1821.
61. Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001; 103: 375-380.
62. Ghali JK, Pina IL, Gottlieb SS, Deedwania PC, Wikstrand JC, MERIT-HF Study Group, Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002; 105: 1585-1591.
63. Ghali JK, Krause-Steinrauf HJ, Adams KF, et al. Gender differences in advanced heart failure:insights from the BEST study. J Am Coll Cardiol 2003; 42: 2128-2134.
64. Johnstone D, Limacher M, Rousseau M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992; 70: 894-900.
65. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72: 310-313.
66. Tofler GH, Stone PH, Muller JE, et al. Effects of gender and race on prognosis after myocardial infarction:adverse prognosis for women, particularly black women. J Am Coll Cardiol 1987; 9: 473-482.
67. Hoffman RM, Psaty BM, Kronmal RA. Modifiable risk factors for incident heart failure in the coronary artery surgery study. Arch Intern Med 1994; 154:417-423.
68. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1998; 98: 1279-1285.
69. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus:a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77:1017-1020.
70. Codd MB, Sugrue DD, Gersh BJ, Melton J 3rd. Epidemiology of idiopathic dilated and hypertropic cardiomyopathy: a population-based study in Olmstead County, Minnesota, 1975-1984. Circulation 1989; 80: 564-572.
71. Bagger JP, Baandrup U, Rasmussen K, Moller M, Vesterlund T. Cardiomyopathy in western Denmark. Br Heart J 1984; 52: 327-331.
72. Williams DG, Olsen EG. Prevalence of overt dilated cardiomyopathy in two regions of England. Br Heart J 1985; 54: 153-155.
73. He J, Ogden LG, Bazzano LA, et al. Risk factors for congestive heart failure in US men and women:NHANES I epidemiologic follow-up study. Arch Intern Med 2001; 161: 996-1002.
74. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989; 320: 409-415.
75. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 1995; 274: 149-154.
76. Fernandez-Sola J, Estruch R, Nicolas JM, et al. Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 1997; 80: 481-485.
77. Walsh CR, Larson MG, Evans JC, et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann Intern Med 2002; 136: 181-191.
78. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347:305-313.
79. Lorell BH. ACE inhibitors after myocardial infarction. N Engl J Med 1993; 328: 966-969. (Letter)
80. Pfeffer MA, Braunwald, E, Moye, LA. ACE inhibitors after myocardial infarction. N Engl J Med 1993; 328: 966-969 (Letter).
81. Limacher MC, Yusuf S, SOLVD Investigators. Gender differences in presentation, morbidity and mortality in the Studies Of Left Ventricular Dysfunction (SOLVD): a preliminary report. In:Wenger NK, Speroff L, Packard B (eds) Cardiovascular Health and Disease in Women (LeJacq Communications: Greenwich, CT, 1993), 345-348.
82. Garg R, Yusuf S, Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.
83. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411.
84. Luzier AB, Killian A, Wilton JH, et al. Genderrelated effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 1999; 66: 594-601.
85. Reis SE, Holubkov R, Young JB, et al. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. J Am Coll Cardiol 2000; 36: 529-533.
86. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ. BEST investigators. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol 2003; 42:1238-1245.
87. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flowmediated vasodilation in post-menopausal women. Ann Intern Med 1994; 121: 936-941.
88. Haq S, Choukroun G, Lim H, et al. Differential activation of signal transduction pathways in human hearts with hypertrophy versus advanced heart failure. Circulation 2001; 103: 670-677.
89. Shah MR, Granger CB, Bart BA, et al. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the Study of Patients Intolerant of Converting Enzyme Inhibitors registry. Am J Med 2000; 109: 489-492.
90. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy. Arch Intern Med 1996; 156: 1669-1673.
91. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460-2464.
92. Blackman IC, Bond, M, Bowling A, et al. Age and sex do not bias the use of angiotensin-converting enzyme inhibitors in acute myocardial infarction and congestive heart failure. J Am Geriatr Soc 2003; 51:572-573 (Letter).
93. Echemann M, Zannad F, Briancon S, et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am Heart J 2000; 139: 624-631.
94. Hood S, Taylor S, Roeves A, et al. Are there any age and sex differences in the investigation and treatment of heart failure? A population based study. Br J Gen Pract 2000; 50: 559-563.
95. Kostis JB, Shelton BJ, Yusuf S, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 1994; 128: 358-364.
96. Kostis JB, Shelton B, Gosselin G, et al. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD investigators. Am Heart J 1996; 131: 350-355.
97. Schleman K, Realson R, Robertson AD, Lindenfeld J. Cough is more common in women than men with heart failure regardless of medical therapy. J Am Coll Cardiol 2001; 37: 212A (Abstract).
98. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994; 154:433-437.
99. Chin MH, Goldman L. Gender differences in 1-year survival and quality of life among patients with congestive heart failure. Med Care 1998; 36:1033-1046.
100. Riegel B, Moser DK, Carlson B, et al. Gender differences in quality of life are minimal in patients with heart failure. J Card Fail 2003: 9: 42-48.
101. Evangelista LS, Dracup K, Doering L, et al. Emotional well-being of heart failure patients and their caregivers. J Card Fail 2002: 8: 300-305.
102. Riedinger MS, Dracup KA, Brecht ML, Padilla G, Sarna L, Ganz PA. Quality of life in patients with heart failure: do gender differences exist? Heart Lung 2001; 30: 105-116.
103. Tyni-Lenné R, Gordon A, Europe E, Jansson E, Sylvén C. Exercise-based rehabilitation improves skeletal muscle capacity, exercise tolerance, and quality of life in both women and men with chronic heart failure. J Card Fail 1998; 4: 9-17.
104. Rostagno C, Galanti G, Romano M, Chiostri G, Gensini GF. Prognostic value of 6-minute walk corridor testing in women with mild to moderate heart failure. Ital Heart J 2002; 3: 109-113.
105. Keteyian SJ, Duscha BD, Brawner CA, et al. Differential effects of exercise training in men and women with chronic heart failure. Am Heart J 2003; 145: 912-918.
106. Duscha BD, Annex BH, Keteyian SJ, et al. Differences in skeletal muscle between men and women with chronic heart failure. J Appl Physiol 2001; 90: 280-286.
107. Duscha BD, Annex BH, Green HJ, Pippen AM, Kraus WE. Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. J Am Coll Cardiol 2002; 39: 1170-1174.
108. Aronson D, Burger AJ. The effect of sex on ventricular arrhythmic events in patients with congestive heart failure. Pacing Clin Electrophysiol 2002; 25:1206-1211.
109. Aronson D, Burger AJ. Gender-related differences in modulation of heart rate in patients with congestive heart failure. J Cardiovasc Electrophysiol 2000; 11:1071-1077.
110. Manolio TA, Furberg CD, Rautaharju PM, et al. Cardiac arrhythmias on 24-h ambulatory electrocardiography in older women and men: the Cardiovascular Health Study. J Am Coll Cardiol 1994; 23: 916-925.
111. Ghali J, Cooper R, Ford E. Trends in hospitalization for heart failure in the United States, 1973-1986:evidence for increasing population prevalence. Arch Intern Med 1990; 150: 769-773.
112. Croft JB, Giles WH, Pollard RA, et al. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997; 45: 270-275.
113. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure:National Hospital Discharge Survey, 1985-1995. Am Heart J 1999; 137: 352-360.
114. Burns RB, McCarthy EP, Moskowitz MA, et al. Outcomes for older men and women with congestive heart failure. J Am Geriatr Soc 1997; 45: 276-280.
115. Vaccarino V, Chen Y, Wang Y, Radford MJ, Krumholz HM. Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J 1999; 138: 835-842.
116. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med 1997; 157: 99-104.
117. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in Case Fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 1126-1131.
118. McMurray J, Morrison C. Increase in hospital admission rates for heart failure in The Netherlands, 1980-1993. Heart 1997; 78: 421-422.
119. Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol 1998; 82: 76-81.
120. Davis K. The Unfinished Agenda: Improving the Well-Being of Elderly People Living Alone. Final report of The Commonwealth Fund Commission on Elderly People Living Alone (The Commonwealth Fund: New York, 1993).
121. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1074-1080.
122. Organ Procurement and Transplantation Network. Transplants in the U.S. by Recipient Gender. Available at: http://www.optn.org/latestData/rptData.asp. Accessed January 15, 2004.
123. Aaronson KD, Schwartz JS, Goin JE, Mancini DM. Sex differences in patients acceptance of cardiac transplant candidacy. Circulation 1995; 91:2753-2761.
124. Opasich C, Tavazzi L, Lucci D, et al. on behalf of the Italian Network on Congestive Heart Failure (INCHF) Investigators. Comparison of one-year outcome in women versus men with chronic congestive heart failure. Am J Cardiol 2000; 86: 353-357.
125. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a populationbased study. Arch Intern Med 2002; 162:1689-1694.
126. Croft JB, Giles WH, Pollard RA, et al. Heart failure survival among older adults in the United States: a poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159:505-510.
127. Zannad F, Briancon S, Juilliere Y, et al. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: The EPICAL Study. J Am Coll Cardiol 1999; 33: 734-742.
128. Bourassa MG, Gurné O, Bangdiwala SI, et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993; 22:14A-19A.
129. Eichhorn EJ. Prognosis determination in heart failure. Am J Med 2001; 110: 14-35.
130. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993; 87: V15-16.
131. Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. J Am Coll Cardiol 1998; 32: 695-703.
132. Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 2001; 13: 1428-1433.
133. Baldasseroni S, Opasich C, Gorini M, et al. Italian Network on Congestive Heart Failure Investigators. Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with symptomatic heart failure: a report from the Italian network on congestive heart failure. Am Heart J 2002; 143: 398-405.